ANIKA THERAPEUTICS, INC.

Anika Therapeutics is a global leader in hyaluronic acid (HA)-based orthopedic regenerative solutions and osteoarthritis pain management. Founded with 30+ years of HA expertise, the company develops and markets innovative treatments addressing rotator cuff and tendon repair, cartilage regeneration, bone augmentation, and non-opioid osteoarthritis pain management. The company operates through two primary product platforms: Regenerative Solutions (tissue repair and scaffold-based regeneration) and OA Pain Management (HA viscosupplements and combination therapies). Key products include Integrity (HA-based rotator cuff and tendon repair augmentation), Hyalofast (cartilage regeneration scaffold), Tactoset (injectable bone substitute), NanoFx (bone marrow stimulation), Cingal (combination HA + steroid injection), Monovisc (single-injection HA viscosupplement), and Orthovisc (multi-injection HA viscosupplement). Products are clinically validated with robust safety and efficacy data supporting use in orthopedic surgery and rheumatology. Anika maintains US headquarters in Bedford, MA, with operational offices in Warsaw, IN, and significant EU presence in Padova, Italy. The company distributes products in 45+ countries globally through direct sales, distribution partnerships, and strategic alliances including J&J MedTech for US Orthovisc and Monovisc distribution. Regulatory credentials and certifications align with FDA, CE marking, and ISO standards for medical devices. The company serves orthopedic surgeons, rheumatologists, pain management specialists, and healthcare institutions seeking regenerative and conservative OA treatment alternatives.